XML 27 R20.htm IDEA: XBRL DOCUMENT v3.25.1
Summary of Significant Accounting Policies (Tables)
3 Months Ended
Mar. 31, 2025
Accounting Policies [Abstract]  
Schedule of Segment Reporting

 

 

For the Three Months
Ended March 31,

 

 

 

2025

 

 

2024

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

Tegoprubart - kidney transplantation programs

 

$

8,531

 

 

$

4,497

 

Tegoprubart - other development programs

 

 

(168

)

 

 

72

 

Manufacturing

 

 

1,670

 

 

 

777

 

Personnel-related

 

 

3,448

 

 

 

2,526

 

Stock-based compensation

 

 

2,864

 

 

 

1,694

 

Other operating expenses

 

 

1,619

 

 

 

1,303

 

Total operating expenses

 

 

17,964

 

 

 

10,869

 

Loss from operations

 

 

(17,964

)

 

 

(10,869

)

Other income, net

 

 

1,409

 

 

 

574

 

Change in fair value of warrant liabilities and fair value of financial instruments issued in excess of proceeds

 

 

10,060

 

 

 

(13,336

)

Segment and net loss

 

$

(6,495

)

 

$

(23,631

)